Posted 25 July, 2023
TScan Therapeutics, Inc. appointed new CEO
CEO Change detected for ticker Nasdaq:TCRX in a 8-K filed on 25 July, 2023.
On July 20, 2023, the Board of Directors (the "Board") of TScan Therapeutics, Inc. (the "Company") appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023, replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023. Dr. MacBeath has been serving as Chief Executive Officer since May 24, 2023.
$310M
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 20, 2023, the Board of Directors (the "Board") of TScan Therapeutics, Inc. (the "Company") appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023, replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023. Dr. MacBeath has been serving as Chief Executive Officer since May 24, 2023. On July 20, 2023, the Board appointed Leiden Dworak as Principal Accounting Officer of the Company, effective July 21, 2023, in which capacity Mr. Silver had previously served. Mr. Dworak has served as Vice President, Finance since April 2022. He has 15 years of experience in financial infrastructure implementation for clinical and manufacturing operations in the biotechnology and life sciences industries. Prior to joining the Company, Mr. Dworak was the Vice President, Head of Financial Planning and Analysis and Business Operations at AVROBIO, Inc., where he implemented a financial infrastructure and developed processes to enable the annual operating plan, strategic plan, and financial reporting. Before joining AVROBIO, Mr. Dworak was a Director at Moderna, Inc., where he was a key strategic business partner across multiple therapeutic areas and the finance lead for global vaccines business development. Prior to that, Mr. Dworak held positions of increasing responsibility for various biotech and pharmaceutical companies including Merrimack Pharmaceuticals, Inc., SeraCare Life Sciences Inc. (now LGC Clinical Diagnostics, Inc.), and Boston Scientific Corporation. Mr. Dworak has a MBA from Indiana University, Bloomington, Indiana. In connection with Mr. Dworak's appointment as Principal Accounting Officer of the Company, the Board agreed to increase his base salary to $340,000 from $321,000, and his target annual bonus to 35% from 30% of his base salary. Mr. Dworak also received an award of stock options for 25,000 shares of voting common stock with an exercise price equal to the closing price on the Nasdaq Global Market on the July 21, 2023 grant date of $2.23 per share. These options would vest over four years, with 25% vesting on the one-year anniversary of the date of grant and the balance in 36 monthly installments thereafter, subject to Mr. Dworak's continued employment. There are no family relationships between Dr. MacBeath or Mr. Dworak, respectively, and any other director, executive officer or nominees thereof of the Company. There are no related party transactions between the Company and Dr. MacBeath or Mr. Dworak, respectively, that would require disclosure under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.